

September 6, 2022

VIA SEDAR

Ontario Securities Commission
Alberta Securities Commission
British Columbia Securities Commission

Dear Sirs/Mesdames:

Re: Satellos Bioscience Inc. (the “Company”) – Final Short Form Prospectus dated September 6, 2022

We refer to the final short form prospectus of the Company dated September 6, 2022 (the “**Prospectus**”) relating to the sale and distribution of units of the Company (“**Units**”) comprised of common shares and common share purchase warrants of the Company at a price of \$0.40 per Unit for aggregate gross proceeds of a minimum of \$3,500,000 and a maximum of \$5,000,000.

We hereby consent to the references to our firm name on the face page of the Prospectus and under the heading “*Legal Matters*”. We also consent to the references to our firm name and to the use of our opinion under the headings “*Eligibility for Investment*” and “*Certain Canadian Federal Income Tax Considerations*”.

We confirm that we have read the Prospectus and have no reason to believe that there are any misrepresentations in the information contained in the Prospectus that is derived from our opinion referred to above or that is within our knowledge as a result of the services we performed in connection with such opinion.

Yours truly,

(signed) “*Borden Ladner Gervais LLP*”

Borden Ladner Gervais LLP